// App-Quantinova.ai

2486 : Docetaxel resistant cells display cancer stem cell properties and regulate growth via PI3/Akt signaling

Researchers

Presenter

  • Prithy C. Martis

Principal Investigators

  • Melissa A. Laramore

  • Hunter L. Gazda

  • Atira Dudley

  • Pradeep R. Dumpala

  • Allyson J. Ocean

  • Nathaniel Berman

  • Tapan Parikh

  • Zoe P. Andrada

  • Angelica Nazarian

  • Joanne Thomas

  • Eugene Akahoho

  • George Stoms

  • Alex Yaroshinsky

  • Thomas J. Fahey

  • David J. Wolf

  • Lawrence S. Gazda

  • Barry H. Smith

Medical Centers

  • The Rogosin Institute - Xenia Division, Xenia, OH

  • Weill Cornell Medical College, New York, NY

  • The Rogosin Institute, New York, NY

  • Vital Systems, Rolling Meadows, IL

  • NewYork-Presbyterian Hospital, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • Peptidase inhibitor 3

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved